U.S., Nov. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07236320) titled 'Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC' on Nov. 15.
Brief Summary: This retrospective real-world study aimed to compare neoadjuvant immunochemotherapy (NICT) and neoadjuvant chemoradiotherapy (NCRT) followed by esophagectomy in patients with locally advanced esophageal squamous cell carcinoma (ESCC). A total of 203 consecutive patients treated at Sichuan Cancer Hospital between March 2018 and March 2022 were analyzed (NICT: 59; NCRT: 144). The primary endpoints were overall survival (OS) and disease-free survival (DFS); secondary endpoints included pathological complete response (pCR), tumor regression grade (TR...